西格列汀联合二甲双胍治疗Ⅱ型糖尿病的疗效观察

摘要

目的:观察T2DM抑制剂西格列汀联合二甲双胍治疗Ⅱ型糖尿病在降低血糖、血脂以及减轻胰岛素抵抗、肥胖方面的作用,并观察其与单独使用胰岛素治疗Ⅱ型糖尿病(T2DM)的临床疗效.方法:选择120例符合T2DM标准的患者,所选患者均有口服降血糖药物史且无使用二甲双胍禁忌症.患者随机分为两组,实验组每天服用西格列汀和二甲双胍一次,对照组单纯使用胰岛素治疗.观察14周前后FBG、2hBG、FINS、HbAIC、TC、TG、LDL-C、HDL-C、HOMA-IR、BMI等指标的变化.结果:西格列汀联合二甲双胍实验组和单纯使用胰岛素的治疗组都能明显降低T2DM患者血糖、血脂,西格列汀联合二甲双胍治疗组可以显著降低胰岛素抵抗和控制体重,胰岛素组却无明显作用.结论:二肽基肽酶-4抑制剂西格列汀联合二甲双胍不仅能显著降低患者患者的血糖、血脂,而且能显著降低胰岛素抵抗及控制体重.%Objective: To explore the effect of combination of sitagliptin and metformin in decreasing blood glucose, lowering blood lipid, reducing insulin resistance, and controlling obesity on patients with type II diabetes. Method: 120 type II diabetes patients who meet the T2DM standard were selected, all patients had history of taking oral hypoglycemic drugs and without contraindications of metformin. The patients were randomly divided into 2 groups,. Experimental group and control group. The patients in experimental group took sitagliptin and metformin once per day, the patients in control group take Insulin once a day. 14 weeks later, the indications FBG, 2hBG, FINS, HbAlC, TC, TG, LDL-C, HDL-C, HOMA-IR, BMI were tested to see if there is any change. Result: The patients in both groups had blood glucose decreased and blood lipid lowered; the insulin resistance in patients received combination of sitagliptin and metformin had inhibited significantly and body weight were well controlled, while the insulin resistance and body weight in control group patients did not show significant difference. Conclusion: Combination of inhibitor sitagliptin and metformin can significantly decrease blood glucose, blood lipid of type II diabetes patients, and remarkably inhibit insulin resistance, control body weight.